Affiliation:
1. Radiopharmacy Department, Uruguayan Centre of Molecular Imaging (CUDIM), Montevideo, Uruguay
Abstract
Background:
The radiolabelling of receptor-binding peptides for therapy is a challenge
since the peptide itself is exposed (during labelling, storage and transport) to radiation-induced damage,
directly or indirectly, in aqueous solution. Hence, the use of radiostabilizers seems to be mandatory,
especially in peptide molecules that contain radiation-sensitive amino acids.
Objective:
The aim of this study was to investigate the effect of two stabilizers, gentisic acid and methionine,
to delve into how each of them affects the radiolabelling and stability of the minigastrin analogue
[177Lu]Lu-DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 through the analysis of the
22 species distinguished over time by an optimized HPLC system.
Methods:
The stabilizers, in different combinations, were present from the beginning of the labelling
process carried out at 96 °C for 15 min. The stability was studied for up to 7 days.
Results:
The unexpected selective oxidation of the methionine residue of the radiolabelled peptide,
promoted by gentisic acid, led to studying the effect of pH, from 3.5 to 6.0, in the presence of only this
stabilizer. A pH-dependent antioxidant behaviour was revealed, showing a decrease in peptide impurities
but an increase in the selective oxidation as the pH was increased.
Conclusion:
The selective oxidation of the methionine residue could be induced by oxidizing species
probably produced in the reaction between gentisic acid and free radicals of water, during the protection
of the radiolabelled peptide from the attack of these harmful species. Therefore, the addition of
methionine becomes necessary to effectively decrease this selective oxidation in the methioninecontaining
peptide.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Radiology, Nuclear Medicine and imaging
Reference36 articles.
1. de Jong,M.; Verwijnen, S.M.; de Visser,M.; Kwekkeboom, D.J.; Valkema,R.; Krenning, E.P. Peptides for Radionuclide Ther-apy.Targeted Radionuclide Tumor Therapy. Biological Aspects, 1st ed; Stigbrand,T.; Carlsson,J.; Adams, G.P. Eds.; Springer. 2008,117-144. http://dx.doi.org/10.1007/978-1-4020-8696-0_7
2. Roman,S.; Lin,R.; Sosa, J.A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of sur-vival in 1252 cases. Cancer. 2006,107(9),2134-2142. http://dx.doi.org/10.1002/cncr.22244 PMID: 17019736
3. Šabani,M.; Jelovac, D.B.; Petrovic, M.B.; Gavric, M. Management of advanced medullary thyroid carcinoma, J. Tumor. 2014,2,202-207
4. Pawlak,D.; Rangger,C.; Kolenc Peitl,P.; Garnuszek,P.; Maurin,M.; Ihli,L.; Kroselj,M.; Maina,T.; Maecke,H.; Erba,P.; Kremser,L.; Hubalewska-Dydejczyk,A.; Mikolajczak,R.; Decristoforo, C. From preclinical development to clinical application: Kit formula-tion for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial. Eur, J. Pharm. Sci. 2016,85,1-9. http://dx.doi.org/10.1016/j.ejps.2016.01.023 PMID: 26826279
5. Reubi, J.C.; Schaer, J-C.; Waser, B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997,57(7),1377-1386. PMID: 9102227
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献